Abstract
Milatuzumab (hLL1), a humanized anti-CD74 monoclonal antibody, has activity in preclinical non-Hodgkin lymphoma (NHL) models. We conducted a phase 1 trial in previously treated B-cell malignancies. Dose escalation included four planned dose levels (1.5, 4, 6 and 8 mg/kg) with milatuzumab given twice weekly for 6 weeks. After dose level 1, the schedule was changed to daily (Monday-Friday) for 10 days. Twenty-two patients were treated. The most common possibly related toxicities were infusion reaction, anemia, lymphopenia, neutropenia and thrombocytopenia. Three patients experienced dose-limiting toxicity (neutropenia, neutropenia, rash) at dose levels 1, 2 and 4, respectively. Eight patients had stable disease, with no objective responses. The serum half-life of milatuzumab was ∼2 h. In seven patients, In-111 imaging showed no clear evidence of tumor targeting. The short half-life may reflect CD74 rapid internalization and presence on extratumoral tissues; this antigen sink must be overcome to capitalize on the promising preclinical activity of the drug.
References
Jan 1, 1994·Annual Review of Immunology·P Cresswell
Dec 14, 1999·Immunology·G L OngM J Mattes
Jan 24, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Harmonization Project on Lymphoma
Sep 19, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rhona SteinDavid M Goldenberg
Sep 19, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Peter MartinJohn P Leonard
Jan 25, 2008·Blood·Michael HallekUNKNOWN International Workshop on Chronic Lymphocytic Leukemia
Dec 5, 2008·Expert Opinion on Investigational Drugs·Tomer MarkRuben Niesvizky
Jan 7, 2011·Expert Opinion on Therapeutic Targets·Federica Borghese, Felix I L Clanchy
Mar 23, 2011·Leukemia & Lymphoma·Idit Shachar, Michal Haran
Jan 25, 2012·Blood·Pankaj GuptaChien-Hsing Chang
Dec 5, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yicheng MaoNatarajan Muthusamy
Feb 22, 2013·Molecular Cancer Therapeutics·Serengulam V GovindanDavid M Goldenberg
Oct 12, 2013·British Journal of Haematology·Jonathan L KaufmanDavid M Goldenberg
Citations
Oct 19, 2016·Inflammation Research : Official Journal of the European Histamine Research Society ... [et Al.]·Huiting SuYong Zhao
May 4, 2017·British Journal of Haematology·Michal HaranLev Shvidel
Feb 22, 2017·The Journal of Immunology : Official Journal of the American Association of Immunologists·Yi ZhouGuo-Ping Shi
Sep 8, 2018·The Journal of Pathology. Clinical Research·Shuchun ZhaoYasodha Natkunam
Oct 28, 2018·The Journal of Biological Chemistry·Rudranil DeUday Bandyopadhyay
Feb 7, 2018·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Amanda SparkesBenoît Stijlemans
May 1, 2018·Oncotarget·Katia ManganoFerdinando Nicoletti
Apr 14, 2017·Oncoimmunology·Annika NeldeAlexander N R Weber
Jun 21, 2018·PloS One·Lara Valiño-RivasMaria Dolores Sanchez-Niño
Feb 26, 2019·Frontiers in Immunology·Smita Y PatelStephen Jolles
Jun 20, 2020·Journal of Hematology & Oncology·Walter Hanel, Narendranath Epperla
Feb 24, 2021·Annals of the Rheumatic Diseases·Daniel J WallaceDavid M Goldenberg
Aug 16, 2021·The Journal of Biological Chemistry·Benjamin SchoepsAchim Krüger